[go: up one dir, main page]

PL304941A1 - Method of simulating a human immune system of patients suffering infections associated with hiv viral infection - Google Patents

Method of simulating a human immune system of patients suffering infections associated with hiv viral infection

Info

Publication number
PL304941A1
PL304941A1 PL94304941A PL30494194A PL304941A1 PL 304941 A1 PL304941 A1 PL 304941A1 PL 94304941 A PL94304941 A PL 94304941A PL 30494194 A PL30494194 A PL 30494194A PL 304941 A1 PL304941 A1 PL 304941A1
Authority
PL
Poland
Prior art keywords
simulating
immune system
viral infection
patients suffering
human immune
Prior art date
Application number
PL94304941A
Inventor
Heinz Schneider
Original Assignee
Sandoz Nutrition Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Nutrition Ltd filed Critical Sandoz Nutrition Ltd
Publication of PL304941A1 publication Critical patent/PL304941A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL94304941A 1993-09-08 1994-09-06 Method of simulating a human immune system of patients suffering infections associated with hiv viral infection PL304941A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939318611A GB9318611D0 (en) 1993-09-08 1993-09-08 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
PL304941A1 true PL304941A1 (en) 1995-03-20

Family

ID=10741694

Family Applications (1)

Application Number Title Priority Date Filing Date
PL94304941A PL304941A1 (en) 1993-09-08 1994-09-06 Method of simulating a human immune system of patients suffering infections associated with hiv viral infection

Country Status (11)

Country Link
EP (1) EP0641562A1 (en)
JP (1) JPH07149664A (en)
CN (1) CN1106296A (en)
AU (1) AU7167394A (en)
CA (1) CA2131512A1 (en)
CZ (1) CZ215694A3 (en)
GB (1) GB9318611D0 (en)
HU (1) HUT67889A (en)
PL (1) PL304941A1 (en)
RU (1) RU94032291A (en)
SK (1) SK106594A3 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
US5856149A (en) * 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids
PL185442B1 (en) * 1996-10-03 2003-05-30 Georgiades Biotech Ltd Pharmaceutic agent exhibiting immunoregulating and psychotropic properties, therapeutic form thereof and method of treating diseases of immunological and physical background
ID24710A (en) * 1998-05-12 2000-08-03 Nutricia Nv NUTRITION COMPOSITION FOR WOUND CARE BECAUSE OF PRESSURE
DE19836339B4 (en) 1998-08-11 2011-12-22 N.V. Nutricia carbohydrate mix
EP1023843B1 (en) * 1999-01-29 2005-06-22 Sportmedizin Team Vertriebs GmbH Composition for improving performance during sportive activities, its production and use as dietetic food product
NL1019368C2 (en) * 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
DE10309368A1 (en) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmaceutical preparation with RNA as a cofactor of hemostasis
JP2007507441A (en) * 2003-10-01 2007-03-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Immune system activation composition
JP4671092B2 (en) * 2003-11-20 2011-04-13 森重 文江 Virus infection prevention and countermeasures
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
PL1758469T5 (en) * 2004-06-22 2014-01-31 Nutricia Nv Improvement of barrier integrity in hiv patients by use of fatty acids
ES2632967T3 (en) 2008-09-02 2017-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of use thereof
RU2538691C2 (en) 2009-04-29 2015-01-10 Амарин Фарма, Инк. Stable pharmaceutical compositions and methods for using them
BRPI1014405A2 (en) 2009-04-29 2016-04-05 Amarin Corp Plc pharmaceutical compositions comprising epa and a cardiovascular agent and methods of their use
DK3318255T3 (en) 2009-06-15 2021-06-07 Amarin Pharmaceuticals Ie Ltd COMPOSITIONS AND PROCEDURES FOR TREATMENT IN A PATIENT IN CONTINUOUS STATIN THERAPY
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (en) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject
CN104582698A (en) 2012-06-29 2015-04-29 阿玛林制药爱尔兰有限公司 Methods of reducing the risk of cardiovascular events in subjects receiving statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (en) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 Compositions and Methods for Lowering Triglycerides in a Subject Having Reduced Kidney Function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN109260229A (en) * 2018-08-23 2019-01-25 辅必成（上海）医药科技有限公司 A kind of oral nutrient lotion comprising fish oil
KR20210110890A (en) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 Methods of reducing the risk of cardiovascular events in a subject
US20220273686A1 (en) * 2019-08-06 2022-09-01 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Pharmaceutical composition for producing safe amount of nitric oxide and use thereof
EP4326244A4 (en) 2021-04-21 2025-03-19 Amarin Pharmaceuticals Ie Ltd METHODS TO REDUCE THE RISK OF HEART FAILURE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
DE3878812T2 (en) * 1987-02-20 1993-07-22 Shriners Hospitals For Cripple OMEGA-3 FATTY ACIDS FOR THE TREATMENT OF TRAUMATIC Wounds.
HU209973B (en) * 1988-03-09 1995-01-30 Biorex Kutato Fejlesztoe Kft Process for production of antiviral and immunstimular pharmaceutical composition
EP0367724B1 (en) * 1988-10-31 1993-02-10 Sandoz Nutrition Ltd. Improvements in or relating to organic compounds
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients

Also Published As

Publication number Publication date
EP0641562A1 (en) 1995-03-08
HUT67889A (en) 1995-05-29
RU94032291A (en) 1996-07-10
CN1106296A (en) 1995-08-09
CZ215694A3 (en) 1995-04-12
HU9402566D0 (en) 1994-10-28
GB9318611D0 (en) 1993-10-27
SK106594A3 (en) 1995-09-13
CA2131512A1 (en) 1995-03-09
AU7167394A (en) 1995-03-23
JPH07149664A (en) 1995-06-13

Similar Documents

Publication Publication Date Title
PL304941A1 (en) Method of simulating a human immune system of patients suffering infections associated with hiv viral infection
EP0831873A4 (en) The treatment of hiv and other viral infections using combinatory therapy
AU7557494A (en) Infection resistant medical devices
AU4028895A (en) Vaccine and treatment method of Human Immunodeficiency Virus
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
ZA90245B (en) Treatment of diseases associated with hiv infections
AU7973994A (en) Combination therapy for hiv infection
DE3277726D1 (en) Use of alkaloid derivatives for the manufacture of a medicament for the strengthening of the immune system and for the treatment of viral, bacterial and fungal infections
HU9202095D0 (en) Therapy and vaccine against aids
AU658987B2 (en) Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection
GB9304746D0 (en) Treatment of viral infections
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
ZA96722B (en) Combination therapy for hiv infection
ZA903258B (en) Method of suppressing hiv infection
AU5836390A (en) Human lymphoma-associated virus
AU6877991A (en) A method of inactivating human immunodeficiency virus
HU9603567D0 (en) Combination therapy for hiv infection
AU3593095A (en) Method of treatment of human immunodeficiency virus (hiv) infection
IL91807A0 (en) Method of detecting a human b-lymphotropic virus infection
BG42054A1 (en) Exoskeleton system of human limb
IE880770L (en) Treatment of viral infections
NZ233973A (en) Treatment of viral and/or bacterial infections
NZ231322A (en) Treatment of viral and/or bacterial infections
PH27412A (en) Method of treatment of human immunodeficiency virus
AU4660889A (en) Method of treatment of human immunodeficiency virus